Node-positive and metastatic penile cancer: lines of therapy
5 standard-of-care settings across 5 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers | HPV |
|---|---|---|
| Early / localised | 1 | · |
| Locally advanced | 1 | · |
| Advanced, first line | 1 | · |
| Second line | · | 1 |
| Other settings | 1 | · |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Positive sentinel node or resectable palpable nodes | Radical inguinal lymphadenectomy; pelvic lymphadenectomy when two or more inguinal nodes are involved or extranodal extension is found. | EAU-ASCO Collaborative Guideline on Penile Cancer 2023 | 68 |
Locally advanced
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Bulky or fixed inguinal nodes | Neoadjuvant TIP chemotherapy (paclitaxel, ifosfamide, cisplatin) followed by lymphadenectomy in responders; chemoradiotherapy as an alternative within InPACT. | EAU-ASCO Collaborative Guideline on Penile Cancer 2023 | 94 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Metastatic disease | Platinum-based chemotherapy (TIP, paclitaxel-cisplatin, or with fluorouracil); PD-1 antibodies in trials or later lines (pembrolizumab, cemiplimab). | EAU-ASCO Collaborative Guideline on Penile Cancer 2023 | 99 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| HPV | HPV 16-positive recurrent disease | Trials of HPV-directed vaccines with checkpoint inhibition (TG4001 with avelumab). | EAU-ASCO Collaborative Guideline on Penile Cancer 2023 | 24 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | After lymphadenectomy with pelvic nodes or extranodal extension | Adjuvant chemotherapy or chemoradiotherapy, ideally within InPACT because the benefit is unproven. | EAU-ASCO Collaborative Guideline on Penile Cancer 2023 | 93 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.